Comparative Pharmacology
Head-to-head clinical analysis: AQUAMEPHYTON versus KONAKION.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AQUAMEPHYTON versus KONAKION.
AQUAMEPHYTON vs KONAKION
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phytonadione (vitamin K1) is a cofactor for hepatic synthesis of clotting factors II, VII, IX, and X. It promotes the carboxylation of glutamate residues on these factors, enabling calcium binding and coagulation activity.
Phytonadione (vitamin K1) is a fat-soluble vitamin that serves as a cofactor for the hepatic microsomal enzyme vitamin K epoxide reductase, which is responsible for the post-translational carboxylation of glutamic acid residues (Gla residues) on clotting factors II, VII, IX, and X, as well as proteins C and S. Carboxylation allows these factors to bind calcium and phospholipids, enabling their activation in the coagulation cascade.
Phytonadione (vitamin K1) 10 mg IV or IM, once; for non-urgent reversal of anticoagulation, 2.5-5 mg oral, once.
1-10 mg IM or subcutaneously (slow IV infusion over 15-30 min if necessary) once; for warfarin reversal, dose based on INR: 1-2.5 mg PO if INR >5, 2.5-5 mg if INR >9, or 10 mg IV if major bleeding.
None Documented
None Documented
Terminal half-life: ~1.5-2.5 hours (adults); clinical context: short half-life requires repeated dosing for vitamin K deficiency correction; prolonged in liver disease (up to 5-7 hours).
Terminal elimination half-life is 1.5-2.5 hours for phytonadione; clinical effect on INR persists for 24-48 hours.
Renal: minimal (<10% as unchanged drug); biliary/fecal: ~50% as metabolites; enterohepatic circulation occurs.
Primarily fecal via bile (60-70%) and renal (10-20%) as metabolites; unchanged drug excretion is minimal.
Category C
Category C
Vitamin K
Vitamin K